Discover
TARA
Protara Therapeutics, Inc.
4.04
2 x 2.88
2 x 4.83
bid
ask
+
0.22
5.76%
2 @ 05:26 AM
3.85 -0.19 (4.70%)
| Ytd | -24.20% | |
| 1y | 44.29% |
3.77
day range
4.04
2.77
52 week range
7.82
| Open | 3.80 | Prev Close | 3.82 | Low | 3.77 | High | 4.04 | Mkt Cap | 227.07M |
| Vol | 1.39M | Avg Vol | 728.71K | EPS | -1.36 | P/E | N/A | Forward P/E | -1.61 |
| Beta | 1.79 | Short Ratio | 14.46 | Inst. Own | 51.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.64 | 200-d Avg | 5.30 | 1yr Est | 26.40 |
| Income Statement | |||
| Operating Expenses | 19.63M | ||
| Research and Development Expense | 13.56M | ||
| Selling, General and Administrative Expense | 6.07M | ||
| Operating Income | -19.63M | ||
| Net Income | -17.78M | ||
| Net Income Common Stock | -17.78M | ||
| Net Income Common Stock (USD) | -17.78M | ||
| Consolidated Income | -17.78M | ||
| Earnings per Basic Share | -0.31 | ||
| Earnings per Basic Share (USD) | -0.31 | ||
| Earnings per Diluted Share | -0.31 | ||
| Earning Before Interest & Taxes (EBIT) | -17.78M | ||
| Earning Before Interest & Taxes (USD) | -17.78M | ||
| Weighted Average Shares | 57.54M | ||
| Weighted Average Shares Diluted | 57.54M | ||
| Balance Sheet | |||
| Cash and Equivalents | 14.74M | ||
| Cash and Equivalents (USD) | 14.74M | ||
| Investments | 163.44M | ||
| Investments Current | 121.05M | ||
| Investments Non-Current | 42.39M | ||
| Current Assets | 140.00M | ||
| Property, Plant & Equipment Net | 3.56M | ||
| Total Assets | 191.92M | ||
| Debt Current | 1.26M | ||
| Total Debt | 3.06M | ||
| Current Liabilities | 8.92M | ||
| Debt Non-Current | 1.79M | ||
| Total Liabilities | 10.72M | ||
| Accumulated Retained Earnings (Deficit) | -320.20M | ||
| Accumulated Other Comprehensive Income | -364.00K | ||
| Shareholders Equity | 181.21M | ||
| Shareholders Equity (USD) | 181.21M | ||
| Assets Non-Current | 51.93M | ||
| Total Debt (USD) | 3.06M | ||
| Liabilities Non-Current | 1.79M | ||
| Trade and Non-Trade Payables | 4.03M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 90.00K | ||
| Net Cash Flow from Financing | 1.14M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -34.92M | ||
| Issuance (Purchase) of Equity Shares | 1.42M | ||
| Net Cash Flow from Investing | -14.72M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -14.72M | ||
| Net Cash Flow from Operations | -21.34M | ||
| Share Based Compensation | 1.36M | ||